First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
Active, not recruiting · NCT05586061 · Registry updated 2025-02-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer | HER2-positive Gastric Cancer | Active, not recruiting | Phase 2 | 2025-02-07 | NCT05586061 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qilu Hospital of Shandong University | 249 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Central Hospital Affiliated to Shandong First Medical University | Jinan | China | 1 |
| Qilu Hospital of Shandong University | Jinan | China | 138 |
| Qingdao Municipal Hospital (Group) | Qingdao | China | 1 |
| Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry | Jinan | China | 1 |
| The Affiliated Hospital of Qingdao University | Qingdao | China | 50 |
| The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital) | Jinan | China | 3 |
| Yantai Yuhuangding Hospital | Yantai | China | 30 |